KOSDAQBiotech & Pharma034940

ChoA Pharmaceutical

₩1,457▲ 4.22%2026-11-18 close
Market Cap
₩9B
Turnover
₩34,615,249
Volume
20K
Shares out.
6.2M
PER
—
PBR
0.3×
EPS
-₩450
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Narrower Losses, Shrinking Sales, and a Thin Capital Buffer

ChoA Pharmaceutical's standalone operating profit turned positive in Q3 2026, but consolidated operating losses and three straight years of falling sales keep revenue recovery and capital structure as the key tests.

  1. 1

    Revenue fell from KRW 68.9 billion in 2022 to KRW 59.3 billion in 2025, declining in each year from 2023 through 2025.

  2. 2

    Q3 2026 operating loss narrowed to KRW 251 million from the prior-year period, while standalone operating profit turned positive.

  3. 3

    The debt ratio rose to 197.2% at the end of 2025 from 66.6% in 2022, and total equity stood at KRW 21.8 billion.

  4. 4

    The company said cumulative exports through Q3 2026 reached KRW 6.05 billion, already above its full-year 2025 export total of KRW 5.84 billion.

  5. 5

    The KOSDAQ market-cap threshold for maintaining a listing is scheduled to be adjusted to KRW 15 billion from January 2027.

02

Business structure

ChoA Pharmaceutical is an OTC-centered drugmaker that runs a multi-product, small-batch production structure. The company itself has described this OTC-focused model as a factor that delayed profitability improvement alongside cost pressure.

Its flagship product is the digestive remedy Gareo Liquid, first launched in 1989, which is described as the only OTC drug in Korea based on dihydroxydibutyl ether (DHBE).

Gareo passed the MFDS clinical re-evaluation after roughly three years of trials at six domestic medical institutions, and after its August 2026 relaunch about 500,000 units had been supplied to pharmacies by November 2026.

Leading product lines are the iron supplement Hwemartin, the children's nutritional line Jalktone, and the liver-health product Hepatos. For the cumulative period through Q3 2025, Hwemartin sales were KRW 2.7 billion, Jalktone KRW 2.56 billion, and Hepatos in the low KRW 1 billion range.

Domestically, the company points to its pharmacy sales network as a core strength. In early 2026 it named four priority areas: stronger pharmacist partnerships, expanded exports, a more advanced contract manufacturing business, and diversified e-commerce channels.

Exports are widening toward Africa and Japan, anchored by an iron supplement supply contract with Kinmed Pharma of the Democratic Republic of the Congo and an MOU with Japan's Blue Opener.

The company announced entry into pet healthcare in early 2024 and launched a dog product line in July 2025, but it does not disclose detailed sales for that business. A dermo-cosmetics business is also being pursued as a new growth engine.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.5B-₩1.5B−9.6%
2025Q4₩15.8B-₩1.5B−9.5%
2026Q1₩14.7B-₩1.1B−7.6%
2026Q2₩15.2B-₩23,007,215−0.2%
2026Q3₩13.8B-₩300M−1.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩68.9B-₩500M₩600M−0.7%1.1%66.6%
2023₩63B-₩6.8B-₩10.5B−10.9%−25.6%91.5%
2024₩62.7B-₩9.6B-₩9.6B−15.4%−30.6%149.7%
2025₩59.3B-₩6.6B-₩6.8B−11.1%−27.2%197.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results show sales shrinking alongside a persistent loss structure. Revenue fell from KRW 68.9 billion in 2022 to KRW 63 billion in 2023 (down 8.6% year on year), KRW 62.7 billion in 2024 (down 0.4%), and KRW 59.3 billion in 2025 (down 5.4%).

Among 2022 to 2025, 2022 was the largest revenue year and 2025 the smallest. Operating loss widened from KRW 482 million in 2022 to KRW 6.83 billion in 2023 and KRW 9.65 billion in 2024, then narrowed to KRW 6.6 billion in 2025.

The operating margin moved from -0.7% in 2022 to -10.9% in 2023, -15.4% in 2024, and -11.1% in 2025.

Net income attributable to controlling shareholders swung from KRW 561 million in 2022 to a loss of KRW 10.5 billion in 2023, then losses of KRW 9.6 billion in 2024 and KRW 6.81 billion in 2025, with the loss narrowing in the latter two years.

Net income including non-controlling interests, a separate measure, was a loss of KRW 7.36 billion in 2025. Operating cash flow was -KRW 1.44 billion in 2022, -KRW 1.48 billion in 2023, -KRW 4.47 billion in 2024, and -KRW 4.18 billion in 2025.

On a quarterly basis, revenue moved from KRW 15.5 billion in Q3 2025 and KRW 15.8 billion in Q4 2025 to KRW 14.7 billion in Q1 2026, KRW 15.2 billion in Q2 2026, and KRW 13.8 billion in Q3 2026, with Q3 2026 down 10.7% year on year.

Operating loss went from KRW 1.49 billion in Q3 2025 and KRW 1.5 billion in Q4 2025 to KRW 1.12 billion in Q1 2026, KRW 23.01 million in Q2 2026, and KRW 251 million in Q3 2026. Operating losses have been recorded in each of the five quarters from Q3 2025 through Q3 2026.

Net income attributable to controlling shareholders turned positive at KRW 26.14 million in Q1 2026 and reached KRW 500 million in Q2 2026, before a net loss of KRW 246 million in Q3 2026. The sum of net losses attributable to controlling shareholders over the last four quarters is KRW 2.78 billion.

The company attributed the failure of 2025 earnings to rebound to raw material cost increases, intensifying generic competition, and drug price cuts occurring together.

The standalone Q3 2026 operating profit of KRW 145.75 million was reported by the media on November 17, 2026, while the consolidated cumulative operating loss of KRW 1.39 billion remains.

05

Industry analysis

ChoA's core categories are OTC products such as iron supplements, children's nutritional lines, and liver-health remedies. According to a February 2026 report, the company attributed its failure to rebound in 2025 to a combination of rising raw material costs, intensifying generic competition, and drug price cuts.

Raw material prices for the flagship Hwemartin iron line have risen by KRW 30,000 per kilogram since 2024, and L-arginine, used in both the Jalktone and Hepatos lines, has increased in cost by roughly KRW 1,500 per kilogram. Under a multi-product, small-batch model, this cost burden acts as a drag on margins.

The domestic pharmacy channel is a strength in terms of sales reach, but the same channel faces generic competition and pressure from drug price cuts. By contrast, Africa and Southeast Asia, where iron-deficiency anemia is prevalent, are regions the company highlights as export opportunities.

In July 2026 the company said it was expanding its export network to the Democratic Republic of the Congo and other markets after Guatemala. Whether faster export growth and local distribution results can offset the industry headwinds needs to be checked against the quarterly sales mix. The cycle position depends on whether domestic OTC demand stabilizes and raw material costs ease.

06

Outlook

At its New Year ceremony in early 2026, the company said it would make 2026 the starting point of a real rebound, and it outlined a plan to reshape its portfolio and operations around core businesses.

At a extraordinary shareholders meeting on July 7, 2026, a proposal to consolidate common shares at a five-to-one ratio was approved as submitted, and the company said it would focus on raising corporate value and shareholder value in the second half.

On the product side, the company plans to develop a soft-capsule form of Gareo to strengthen its position in the digestive remedy market. In Japan, it is pursuing entry into large retail channels such as Don Quijote, building on its MOU with Blue Opener.

The dermo-cosmetics business is being developed as a new revenue source. Cumulative exports through Q3 2026 reached KRW 6.05 billion, already above the full-year 2025 export total, but a cumulative consolidated operating loss remains, so establishing a profitable structure is still a task.

On the regulatory side, the KOSDAQ market-cap threshold for maintaining a listing is scheduled to be adjusted to KRW 15 billion from January 2027, and to rise to KRW 30 billion by 2029 in stages.

In the 2026 annual report, the next regular filing, the points to check are how annual revenue and operating margin compare with 2025.

07

Valuation

PER
—
PBR
0.3×
ROE
-8.8%
EPS
-₩450
BPS
₩5,682
Dividend per share
₩0

The price-to-book ratio sits below 1x, meaning the share price trades under book value per share. Total equity at the end of 2025 was KRW 21.8 billion, of which the controlling shareholders' stake was reported as KRW 25 billion.

The P/E ratio is not calculated because the net loss attributable to controlling shareholders over the last four quarters totals KRW 2.78 billion. Earnings-based multiples therefore do not capture current profitability, so asset-based measures and cash flow need to be read together.

The dividend is effectively nonexistent. According to media reports, total equity declined from KRW 38.8 billion in 2023 to KRW 28.6 billion in 2024 and KRW 24.4 billion in the third quarter of 2025, while accumulated deficit grew.

The KOSDAQ listing threshold based on market capitalization is set to rise to KRW 15 billion from January 2027, so the company's market value is measured against that rule.

Because the common share consolidation was approved in July 2026, per-share comparisons across time need to account for the pre- and post-consolidation basis.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrower losses and a standalone profit turn

Q3 2026 operating loss narrowed to KRW 251 million from the prior-year period, and Q2 2026 operating loss had already shrunk to KRW 23.01 million. Media reports on November 17, 2026 said standalone Q3 operating profit of KRW 145.75 million turned the year-ago loss into a profit. Whether this carries over to consolidated results is the next test of this bullish case.

Export growth and overseas distribution

The company said cumulative exports through Q3 2026 reached KRW 6.05 billion, above the full-year 2025 total of KRW 5.84 billion. Its export destinations are widening to Africa and Japan through an iron supplement contract with Kinmed Pharma in the Democratic Republic of the Congo and an MOU with Blue Opener.

In July 2026 it said it was expanding its export network to the Democratic Republic of the Congo after Guatemala.

Gareo relaunch and a new dosage form

Gareo Liquid, relaunched in August 2026, had supplied about 500,000 units to pharmacies by November 2026. The company plans to develop a soft-capsule version of Gareo to widen its digestive remedy lineup. It also stresses that the product passed the MFDS clinical re-evaluation and kept its OTC status.

09

Bear factors

Continued sales decline

Revenue fell from KRW 68.9 billion in 2022 to KRW 59.3 billion in 2025, and Q3 2026 revenue of KRW 13.8 billion was down 10.7% year on year. Quarterly sales moved between KRW 14.7 billion and KRW 15.2 billion in the first half of 2026 before dropping to KRW 13.8 billion in Q3.

The company says it is maintaining its existing sales base while growing exports, but a reversal of the domestic decline is not yet visible in quarterly results.

Rising debt and capital erosion concerns

The debt ratio rose from 66.6% in 2022 to 197.2% in 2025, with total liabilities of KRW 42.9 billion at the end of 2025. Total equity at the same point was KRW 21.8 billion.

Media reports said equity fell to KRW 24.4 billion in Q3 2025 as accumulated deficits grew, and that capital raising through rights offerings or convertible bonds has been discussed.

Cost pressure, generics and drug price cuts

According to a February 2026 report, the company said rising raw material prices, intensifying generic competition, and drug price cuts delayed profitability improvement. Raw material costs for all three major product groups were reported to have risen. Operating cash flow stayed negative at -KRW 4.47 billion in 2024 and -KRW 4.18 billion in 2025.

10

Risk factors

Financial capacity risk

Total equity at the end of 2025 was KRW 21.8 billion, and the debt ratio stood at 197.2%. If capital is raised through rights offerings or convertible bonds, existing shareholders' stakes could be diluted. Continued negative operating cash flow also adds to funding needs.

Earnings structure risk

Operating losses have been recorded in each of the five quarters from Q3 2025 through Q3 2026. Q3 2026 revenue was down 10.7% year on year. If raw material costs, generic competition, and drug price cuts act together, margin recovery could be delayed.

Listing maintenance and overseas execution risk

The KOSDAQ market-cap threshold for maintaining a listing is set to be adjusted to KRW 15 billion from January 2027 and to KRW 30 billion by 2029. Export contracts and MOUs need to be confirmed through actual supply volumes and revenue recognition timing. If they do not translate into sales, the effect on reported results may take time.

11

What to watch next

  1. January 2027

    The KOSDAQ market-cap threshold for maintaining a listing is adjusted to KRW 15 billion. The gap between the current market value and this threshold is the key regulatory checkpoint.

  2. Late March 2027

    The 2026 annual report is due. The points to check are annual revenue, operating loss, debt ratio, total equity versus 2025, and the direction of operating cash flow.

  3. Mid-May 2027

    The Q1 2027 quarterly report is due. The key questions are whether consolidated operating results break the five-quarter losing streak and whether the Gareo relaunch shows up in sales.

  4. During 2027

    Check whether the soft-capsule form of Gareo launches and whether Japanese large retail channels are entered. This is based on company plans, and a specific schedule has not been disclosed.

12

Overall view

ChoA Pharmaceutical's standalone operating profit turned positive in Q3 2026, and its consolidated operating loss narrowed from a year earlier, but revenue has declined three straight years from KRW 68.9 billion in 2022 to KRW 59.3 billion in 2025.

The earnings structure is under pressure from raw material costs, generic competition, and drug price cuts, and the debt ratio was 197.2% at the end of 2025.

Taken together with total equity of KRW 21.8 billion and a combined net loss attributable to controlling shareholders of KRW 2.78 billion over the last four quarters, financial capacity is the central variable.

On the bullish side, cumulative exports have already passed the full-year 2025 total and the Gareo relaunch is cited as a basis for recovery. On the bearish side, five straight quarters of operating losses, falling sales, and possible capital raising are linked.

With the share price below book value, a P/E ratio cannot be calculated. The next checkpoints are the KOSDAQ market-cap threshold from January 2027 and the operating margin and total equity in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. supple.kr
  2. kpanews.co.kr
  3. supple.kr
  4. medipana.com
  5. insightkorea.co.kr
  6. m.news.nate.com
  7. getnews.co.kr
  8. dailypharm.com
  9. ibabynews.com
  10. m.news.nate.com
  11. metroseoul.co.kr
  12. vegannews.co.kr
  13. news1.kr
  14. news.nate.com
  15. news.nate.com
  16. v.daum.net

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis